A new oral medication, orforglipron, is showing early success in U.S. trials as a potential follow-up treatment for people who stop taking weekly obesity injections like Wegovy or Ozempic. Unlike daily diet pills of the past, orforglipron belongs to a class of drugs that mimic the action of GLP-1 hormones, similar to the active ingredients in the popular obesity drugs currently on the market.

The compound, developed by Eli Lilly and Company, is designed to be taken once a day as a tablet. Early phase trial results, published in medical journals, indicate it helped participants maintain reduced body weight after discontinuing injectable treatments. Researchers note the drug works by slowing stomach emptying and reducing appetite, mechanisms already proven effective in injectable obesity drugs.

How orforglipron compares to existing treatments

Unlike Wegovy or Ozempic, which contain semaglutide, orforglipron is a non-peptide GLP-1 receptor agonist. This means it delivers similar metabolic benefits—such as improved blood sugar control and reduced hunger—without requiring injections. The pill form could make it more accessible to people uncomfortable with needles or those seeking to transition from injectable treatments.

Clinical trials are ongoing, with larger phase 3 studies expected to begin later this year. Early data shows participants experienced an average weight loss of 8–12% over 36 weeks, comparable to results seen with weekly injections. Side effects reported so far include mild nausea and digestive discomfort, typical of GLP-1 drugs.

Regulatory path and potential UK availability

The U.S. Food and Drug Administration (FDA) is reviewing orforglipron under accelerated approval pathways, with a decision expected by mid-2025. If approved, it would become one of the first oral GLP-1 drugs for long-term weight management in the U.S. The manufacturer has not confirmed timelines for the UK or Europe but has indicated plans to seek global regulatory approval.

Broader implications for obesity treatment

If orforglipron is approved, it could expand treatment options for the estimated 1 billion people worldwide living with obesity. Current injectable GLP-1 drugs require consistent use and can be costly. A once-daily pill may improve adherence and accessibility, particularly in regions where injection therapies are less available.

Doctors warn that orforglipron, like other GLP-1 drugs, is not a quick fix and should be used alongside diet and lifestyle changes. The long-term safety and effectiveness beyond one year are still under study.

Regulators and health systems will need to determine pricing and reimbursement policies if the drug is approved. The obesity drug market is rapidly growing, with global sales expected to surpass $100 billion by 2030, according to industry analysts.

What You Need to Know

  • Source: BBC News
  • Published: May 12, 2026 at 23:06 UTC
  • Category: Health
  • Topics: #bbc · #health · #medicine · #obesity · #nutrition · #daily

Read the Full Story

This is a curated summary. For the complete article, original data, quotes and full analysis:

Read the full story on BBC News →

All reporting rights belong to the respective author(s) at BBC News. GlobalBR News summarizes publicly available content to help readers discover the most relevant global news.

Curated by GlobalBR News · May 12, 2026

🇧🇷 Resumo em Português

Um novo comprimido diário, chamado orforglipron, pode ser a solução para quem luta para manter o peso perdido após interromper injeções contra obesidade, como Wegovy ou Ozempic. A novidade, testada em ensaios clínicos nos Estados Unidos, promete oferecer uma alternativa prática e acessível para pacientes brasileiros que buscam controle de peso a longo prazo, especialmente após o crescente uso dessas medicações injetáveis no país.

No Brasil, onde a obesidade afeta cerca de 22,4% da população adulta, segundo o Ministério da Saúde, a chegada de um medicamento oral como o orforglipron representa um avanço significativo. Até então, a dependência de injeções semestrais ou mensais impunha barreiras logísticas e financeiras para muitos pacientes, além de gerar dúvidas sobre a manutenção dos resultados após a descontinuação. Com eficácia semelhante a tratamentos injetáveis em estudos preliminares, o comprimido poderia democratizar o acesso ao controle de peso sustentável, reduzindo a carga sobre o sistema público de saúde.

Enquanto a aprovação regulatória ainda depende de mais testes e avaliações, a expectativa é que essa inovação chegue rapidamente ao mercado global, redefinindo o futuro do tratamento da obesidade no Brasil e no mundo.

🇪🇸 Resumen en Español

Una pastilla diaria podría revolucionar la lucha contra el sobrepeso tras abandonar los fármacos inyectables para la obesidad. Investigadores estadounidenses han desarrollado orforglipron, un comprimido experimental que, en ensayos clínicos, demostró ser capaz de mantener la pérdida de peso en pacientes que dejaron de usar inyecciones como Wegovy u Ozempic.

El hallazgo abre una esperanza para millones de personas que, tras meses o años de tratamiento con agonistas del receptor GLP-1, ven cómo recuperan los kilos al suspenderlos. Aunque aún está en fase de prueba, este fármaco oral podría simplificar el tratamiento a largo plazo, evitando los efectos rebote y reduciendo la dependencia de las inyecciones. Para los hispanohablantes, especialmente en regiones con altas tasas de obesidad como España o Latinoamérica, donde estos medicamentos son cada vez más accesibles pero aún costosos, la posibilidad de una alternativa más práctica y potencialmente más asequible representa un avance con implicaciones sanitarias y económicas significativas.